Martin Madaus Elected to Hologic Board of Directors
Hologic (HOLX) announced the election of Dr. Martin Madaus to its Board of Directors, effective December 6, 2024. Dr. Madaus brings over 30 years of diagnostics and life sciences industry experience to the board. He currently serves as an Operating Executive at the Carlyle Group, which he joined in February 2019.
Dr. Madaus previously held positions as Chairman and CEO of Ortho Clinical Diagnostics, and served as Chairman, President and CEO of Millipore until its acquisition by Merck KGaA in 2010. He will serve on both the Compensation Committee and the Nominating and Corporate Governance Committee.
Hologic (HOLX) ha annunciato l'elezione del Dr. Martin Madaus nel suo Consiglio di Amministrazione, con effetto dal 6 dicembre 2024. Il Dr. Madaus porta al consiglio oltre 30 anni di esperienza nell'industria dei diagnosti e delle scienze della vita. Attualmente ricopre il ruolo di Executive Operativo presso il Carlyle Group, dove è entrato nel febbraio 2019.
In precedenza, il Dr. Madaus ha ricoperto posizioni come Presidente e CEO di Ortho Clinical Diagnostics, oltre a essere stato Presidente, Direttore Generale e CEO di Millipore fino all'acquisizione da parte di Merck KGaA nel 2010. Farà parte sia del Comitato per la Retribuzione che del Comitato per la Nomina e per la Governance Aziendale.
Hologic (HOLX) anunció la elección del Dr. Martin Madaus en su Junta Directiva, con efecto desde el 6 de diciembre de 2024. El Dr. Madaus aporta más de 30 años de experiencia en la industria de diagnósticos y ciencias de la vida al consejo. Actualmente se desempeña como Ejecutivo Operativo en Carlyle Group, al que se unió en febrero de 2019.
El Dr. Madaus ocupó anteriormente cargos como Presidente y CEO de Ortho Clinical Diagnostics, y fue Presidente, Director General y CEO de Millipore hasta su adquisición por Merck KGaA en 2010. Servirá en el Comité de Compensación y en el Comité de Nominaciones y Gobernanza Corporativa.
Hologic (HOLX)는 2024년 12월 6일부터 Dr. Martin Madaus를 이사로 선출했다고 발표했습니다. Dr. Madaus는 진단 및 생명 과학 산업에서 30년 이상의 경험을 이사회에 제공합니다. 그는 현재 Carlyle Group의 운영 임원으로 재직 중이며, 2019년 2월에 합류했습니다.
Dr. Madaus는 이전에 Ortho Clinical Diagnostics의 의장 및 CEO로 활동했으며, 2010년 Merck KGaA에 인수될 때까지 Millipore의 의장, 사장 및 CEO로 재직했습니다. 그는 보상위원회와 추천 및 기업 거버넌스 위원회 모두에서 활동할 예정입니다.
Hologic (HOLX) a annoncé l'élection du Dr. Martin Madaus à son conseil d'administration, prenant effet le 6 décembre 2024. Le Dr. Madaus apporte plus de 30 ans d'expérience dans l'industrie du diagnostic et des sciences de la vie au conseil. Il occupe actuellement le poste d'Executive Operating au sein de Carlyle Group, qu'il a rejoint en février 2019.
Auparavant, le Dr. Madaus a été Président et PDG d'Ortho Clinical Diagnostics, et il a occupé les fonctions de Président, Directeur Général et PDG de Millipore jusqu'à son acquisition par Merck KGaA en 2010. Il siégera à la fois au Comité de Rémunération et au Comité de Nominations et de Gouvernance d'Entreprise.
Hologic (HOLX) gab die Wahl von Dr. Martin Madaus in seinen Vorstand bekannt, die am 6. Dezember 2024 wirksam wird. Dr. Madaus bringt über 30 Jahre Erfahrung in der Diagnostik- und Lebenswissenschaftsindustrie in den Vorstand ein. Derzeit ist er als Betriebsleiter bei der Carlyle Group tätig, zu der er im Februar 2019 gestoßen ist.
Dr. Madaus hatte zuvor Positionen als Vorsitzender und CEO von Ortho Clinical Diagnostics inne und war bis zur Übernahme durch Merck KGaA im Jahr 2010 Vorsitzender, Präsident und CEO von Millipore. Er wird sowohl im Vergütungsausschuss als auch im Nomination- und Corporate-Governance-Ausschuss tätig sein.
- Addition of board member with extensive diagnostics industry experience
- Strategic expertise from leadership roles at major healthcare companies
- Strengthened corporate governance through experienced executive appointment
- None.
Dr. Martin Madaus (Photo: Business Wire)
Dr. Madaus, who has more than 30 years of diagnostics and life sciences industry experience, currently serves as an Operating Executive at the Carlyle Group, a global investment firm, which he joined in February 2019. Prior to joining the Carlyle Group, Dr. Madaus held the role of Chairman and Chief Executive Officer at Ortho Clinical Diagnostics, Inc., a diagnostics company that makes products and diagnostic testing equipment for blood testing. Dr. Madaus previously served as the Chairman, President and Chief Executive Officer of Milipore Corporation, a life sciences company serving the bioscience research and biopharmaceutical manufacturing industry, until its acquisition by Merck KGaA in 2010.
“We’re delighted to welcome Martin to Hologic’s Board of Directors,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “With his deep industry, technical, business and international experiences, Martin represents yet another strong addition to our deep and experienced Board.”
Dr. Madaus received a Doctor of Veterinary Medicine from the University of
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Forward Looking Statements
This press release contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions, and statements regarding the Company's Board of Directors. These forward-looking statements are based on assumptions made by the Company as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. These risks include, but are not limited to, the risk that the Company may not be able to attract and retain qualified Board members or executives. These risks are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by the Company with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented here to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
SOURCE: Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241209400549/en/
Investor Contact:
Ryan Simon
+1 858.410.8514
ryan.simon@hologic.com
Media Contact:
Bridget Perry
+1 508.263.8654
bridget.perry@hologic.com
Source: Hologic, Inc.
FAQ
When will Martin Madaus join Hologic's (HOLX) Board of Directors?
What committees will Martin Madaus serve on at Hologic (HOLX)?
What is Martin Madaus's current role before joining Hologic's (HOLX) board?
